FontsA A
ContrastA A
Newsletter Sign-Up

BBMRI-LPC

Biobanking and Biomolecular Resources Research Infrastructure – Large Prospective Cohorts

Topic: INFRA-2012-1.1.9

Type of Action: CP&CSA

Duration: 57 months

Start Date: 1 February 2013 – 31 October 2017

BBMRI-ERIC full partner: as of 1 April 2014

Web: http://www.bbmri-lpc.org/

Coordinator: Markus Perola

Co-Coordinator: Gertjan van Ommen

Total requested Grant by Consortium: €8,000,000.00

Total requested Grant by BBMRI-ERIC: €14,552.00

Linked Third Parties/BBMRI-ERIC Framework Agreement: none

Benefit/tasks for BBMRI-ERIC: BBMRI-LPC Forum, BBMRI-ERIC

Abstract

Abstract:

Lead by UH-FIMM.

BBMRI-LPC unites the large study sets of the European Biobanking and Biomolecular resources Research Infrastructure (BBMRI) and the International Agency for Research on Cancer (IARC), thus achieving a worldwide unique scale of integration.

Specifically, we aim to:

  1. Evaluate/improve the harmonisation of individual data on health, lifestyle and other exposures;
  2. Develop/implement harmonised definitions of diseases;
  3. Improve biobanking and research technologies and develop innovative solutions facilitating high-quality, fair transnational access to samples and data;
  4. Provide free transnational access by users, through study proposals selected by an open, pan-European call;
  5. In the framework of these studies, generate and provide access to whole genome sequences, transcriptome, proteome, metabolome and methylome data;
  6. Build new public-private partnerships involving large-scale prospective cohorts, and strengthening existing ones, allowing transparent industrial access to academic expertise;
  7. Build a network transferring the expertise of established European large-scale biobanks to new biobank initiatives under development in other countries (BBMRI-LPC Forum).

 

List of Participants

Helsingin Yliopisto (UH-FIMM); Academisch Ziekenhuis Leiden Leid Universitair Medisch Centrum (LUMC); Centre International de Recherche Sur le Cancer (IARC-WHO); Imperial College of Science, Technology and Medicine (ICL); Medizinische Universitat Graz MEDUNI Graz (MUG); Karolinska Institutet(KI); Genome Research Limited (WTSI); Academisch Ziekenhuis Groningen (UMCG); Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit un Umwelt GmBh (HMGU); Norges Teknisk Naturvitenskapelige Universitet (NTNU); Tartu Ulikool (UTARTU); Uppsala Universitet (UU); Centre Nacional D’Anàlisi Genòmica Fundacio Centre de Regulacio Genomica (CNAG-CRG); Cambridge Protein Arrays LTD (CPA); Pecsi Tudomanyegyetem University of PECS (UP); The Research Institute of the Mc Gill University Health Centre (RI MUHC); Legal Pathways BV (Legal Pathways); Islensk Erfdagreining EHF (DECODE); Terveyden Ja Hyvinvoinnin Laitos (THL); International Prevention ResearchInstitut IPRI Management (IPRI); Latvijas Biomedicinas Petijumu un Studiju Centrs (LBMC); Sveuciliste U Splitu University of SPLIT (CCGH); Wroclawskie Centrum Badan EIT + Sp. z o.o. (EIT+); Klinikum Rechts der Isar der Technischen Universitat Munchen (TUM-MED); Institut national de la Sante et de lat Recherche Medicale (INSERM); MedLawconsult (Medlaw); Universiteit Maastricht (MU); Nasjonalt Folkehelseinstitutt (NIPH); Statens Serum Institut (SSI), University of Bristol (UBRIS), BBMRI-ERIC, Universita Degli Stufi di Milano Bicocca (UNIMIB)


We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies from this website. If you would like to change your preferences you may do so by following the instructions
Accept